TABLE 5.

Consolidated report of adverse events.

Comparation	Azvudine (N = 156)		EAs = 110		Placebo (N = 156)		EAs = 112
Classification	Grade 1		Grade 2		Grade 1		Grade 2
	Case	Subject (%)	Case	Subject (%)	Case	Subject (%)	Case	Subject (%)
Headache	17	10.89	0	0	19	12,17	0	0
Dizziness	16	10.25	0	0	19	12.17	0	0
AST increase	11	7.05	0	0	10	6.41	0	0
Nausea	10	6.4	0	0	9	5.76	0	0
Alt increase	8	5.12	0	0	6	3.84	0	0
Dimer increase d	4	2.56	0	0	7	4.48	0	0
Hyperglycemia	4	2.56	0	0	5	3.20	0	0
IB increase	4	2.56	0	0	4	2.56	0	0
GGT increase	5	3,20	0	0	3	1.92	0	0
PCR-US reduction	1		0	0	7	4.48	0	0
GGT reduction	4	2.56	0	0	2	1.28	0	0
AST reduction	2	1.28	0	0	3	1.92	0	0
BD increase	3	1.92	0	0	1	0.64	0	0
BD reduction	1	0.64	0	0	2	1.28	0	0
ALT reduction	2	1.28	0	0	1	0.64	0	0
Potassium increase	3	1.92	0	0	0	0	0	0
Palpitation	0	0	1	0.64	0	0	1	0.64
CPK-MB increase	0	0	0	0	2	1.28	0	0
Chest pain	0	0	0	0	2	1.28	0	0
Pregnancy	0	0	1	0.64	0	0	0	0
Hypotension	1	0.64	0	0	1	0.64	0	0
Leukocytes increase	2	1.28	0	0	0	0	0	0
PCR-US increase	1	0.64	0	0	0	0	0	0
IB reduction	0	0	0	0	1	0.64	0	0
Lymphocyte reduction	1	0,64	0	0	0	0	0	0
Arrhythmia	0	0	1	0.64	0	0	0	0
Precordial pain	0	0	0	0	0	0	2	1.28
Abdominal pain	1	0.64	0	0	0	0	0	0
Backache	0	0	0	0	1	0.64	0	0
Bradicardia	0	0	0	0	0	0	1	0.64
Arterial hypertension	0	0	0	0	1	0.64	0	0
Epigastralgia	0	0	0	0	1	0.64	0	0
Anxiety	1	0.64	0	0	0	0	0	0
Sodium reduction	1	0.64	0	0	0	0	0	0
Potassium reduction	1	0.64	0	0	0	0	0	0
Tremor in hands	1	0.64	0	0	0	0	0	0
Skin forming	0	0	0	0	1	0.64	0	0
CPK-MB Reduction	1	0.64	0	0	0	0	0	0
Troponin I reduction	1	0.64	0	0	0	0	0	0
Total partial	107	67.87	3	1.92	108	69.15	4	2.56